Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).
NIDDK, Phoenix, Phoenix, Arizona, United States
Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China
Mayo Clinic, Rochester, Minnesota, United States
Vanderbilt University, Nashville, Tennessee, United States
Fracc. Magallanes, Acapulco Guerrero, Mexico
VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
Pramongkutklao Hospital, Bangkok, Thailand
CRC, Med. Klinik 4, University of Erlangen-Nürnberg, Erlangen, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.